• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12B filed by CAI International, Inc.

    12/3/21 11:02:13 AM ET
    $CAI
    Medical Specialities
    Health Care
    Get the next $CAI alert in real time by email
    15-12B 1 brhc10031371_1512b.htm 15-12B
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549



    FORM 15


    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934.
     
    Commission File Number: 001-33388



    CAI INTERNATIONAL, INC.
    (Exact name of registrant as specified in its charter)


    Steuart Tower, 1 Market Plaza, Suite 2400
    San Francisco, California 94105
    (415) 788-0100
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
     
    Common Stock, par value $0.0001 per share
    8.50% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, par value $0.0001 per share
    8.50% Series B Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, par value $0.0001 per share
    (Title of each class of securities covered by this Form)
     
    None
    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)


     
    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     
    Rule 12g-4(a)(1)
    ☒
     
    Rule 12g-4(a)(2)
    ☐
     
    Rule 12h-3(b)(1)(i)
    ☒
     
    Rule 12h-3(b)(1)(ii)
    ☐
     
    Rule 15d-6
    ☐
     
    Rule 15d-22(b)
    ☐
     
    Approximate number of holders of record as of the certification or notice date:
     
    Common Stock, par value $0.0001 per share: One (1) holder*
    8.50% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, par value $0.0001 per share: No holders
    8.50% Series B Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, par value $0.0001 per share: No holders


     
    * On June 17, 2021, CAI International, Inc., a Delaware corporation (the “Registrant”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Mitsubishi HC Capital Inc., a Japanese corporation (“Parent”) and Cattleya Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, on November 22, 2021, Merger Sub merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation in the Merger as a wholly-owned subsidiary of Parent.



    Pursuant to the requirements of the Securities Exchange Act of 1934, CAI International, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
     
    Date: December 3, 2021

     
    CAI INTERNATIONAL, INC.
         
     
    By:
    /s/ Timothy B. Page
       
    Timothy B. Page
       
    President and Chief Executive Officer



    Get the next $CAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAI

    DatePrice TargetRatingAnalyst
    12/2/2025$28.00Hold
    Canaccord Genuity
    7/14/2025$31.00Buy
    BofA Securities
    7/14/2025$31.00Overweight
    Analyst
    7/14/2025$32.00Buy
    Guggenheim
    7/14/2025$33.00Outperform
    Evercore ISI
    7/14/2025$32.00Buy
    TD Cowen
    7/14/2025$38.00Buy
    BTIG Research
    7/14/2025$34.00Buy
    Citigroup
    More analyst ratings

    $CAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Power Luke Thomas exercised 62,250 shares at a strike of $2.44 and sold $1,654,461 worth of shares (62,250 units at $26.58) (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    12/12/25 7:39:15 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Brille Brian J gifted 1,300 shares, decreasing direct ownership by 0.80% to 161,128 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    12/12/25 6:22:53 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel bought $100,793 worth of shares (4,184 units at $24.09) (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:12:42 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium

    IRVING, Texas, Dec. 4, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, including those within the Caris Precision Oncology Alliance ™ (Caris POA), will collectively present 19 studies across a range of breast cancer types at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025. The studies investigated seven distinct breast cancer subtypes, including HR+/HER2–, HER2-positive, H

    12/4/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute

    IRVING, Texas, Dec. 2, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute has joined the Caris Precision Oncology Alliance™ (Caris POA). The Caris POA is a global network of top cancer centers and research groups that work together to advance precision oncology and biomarker-driven research. "It is great to welcome UAMS to the Caris POA. Their unwavering commitmen

    12/2/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class

    IRVING, Texas, Nov. 21, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the selection of 15 physician-scientists to participate in its 2025/2026 Caris Precision Oncology Alliance (Caris POA) Fellows Forum. This competitive two-year program provides early-career oncologists with hands-on training, mentorship and access to real-world molecular data, empowering them to develop and test clinically meaningful precision medicine hypotheses. To be considered for the

    11/21/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Caris Life Sciences with a new price target

    Canaccord Genuity initiated coverage of Caris Life Sciences with a rating of Hold and set a new price target of $28.00

    12/2/25 8:24:07 AM ET
    $CAI
    Medical Specialities
    Health Care

    BofA Securities initiated coverage on Caris Life Sciences with a new price target

    BofA Securities initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $31.00

    7/14/25 8:49:47 AM ET
    $CAI
    Medical Specialities
    Health Care

    Analyst initiated coverage on Caris Life Sciences with a new price target

    Analyst initiated coverage of Caris Life Sciences with a rating of Overweight and set a new price target of $31.00

    7/14/25 8:49:26 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Denton John Russel bought $100,793 worth of shares (4,184 units at $24.09) (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:12:42 AM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley bought $9,540 worth of shares (400 units at $23.85), increasing direct ownership by 0.09% to 460,777 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:11:33 AM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel returned $4,431,078 worth of shares to the company (238,230 units at $18.60), was granted 99,321 shares and bought $157,500 worth of shares (7,500 units at $21.00), decreasing direct ownership by 52% to 123,591 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:34:51 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    SEC Filings

    View All

    SEC Form 10-Q filed by Caris Life Sciences Inc.

    10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)

    11/5/25 5:01:37 PM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Caris Life Sciences, Inc. (0002019410) (Filer)

    11/5/25 4:17:48 PM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Caris Life Sciences, Inc. (0002019410) (Filer)

    10/30/25 4:20:33 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Financials

    Live finance-specific insights

    View All

    Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025

    IRVING, Texas, Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Wednesday, November 5, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/uwjxydsa A replay of the webcast will

    10/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025

    IRVING, Texas, July 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Tuesday, August 12, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/hfsyg967 A replay of the webcast will be a

    7/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    CAI International, Inc. Declares Quarterly Dividend

    CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that CAI's Board of Directors declared a cash dividend of $0.30 per common share payable on September 27, 2021 to shareholders of record as of September 10, 2021. About CAI International, Inc. CAI is one of the world's leading transportation finance companies. As of June 30, 2021, CAI operated a worldwide fleet of approximately 1.9 million CEUs of containers. CAI operates through 13 offices located in 12 countries including the United States. Additional Information and Where to Find It This communication relates to the proposed merger involving the Co

    8/27/21 5:49:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CAI International, Inc. (Amendment)

    SC 13G/A - CAI International, Inc. (0001388430) (Subject)

    12/10/21 10:00:15 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    11/12/21 9:17:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    10/7/21 4:07:36 PM ET
    $CAI
    Medical Specialities
    Health Care